StockData
Lipocine Inc. logo

Lipocine Inc. (LPCN) stock

LPCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3039% below fair value
$1.60−0.06 (-3.61%)

Close on Nov 17, 2026Market cap $13.19MP/E –Yield –

Lipocine pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Lipocine's pe ratio was 11.5× on Jan 31, 2023.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2023Jan 31, 202311.5×+2.9
2022Dec 30, 20228.6×–

More Lipocine figures

See a number that looks wrong?